New Medicine Service (NMS) data definitions

Size: px

Start display at page:

Download "New Medicine Service (NMS) data definitions"

Job Caldwell
6 years ago
Views:

1 New Medicine Service (NMS) data definitions December 2013

2 The data reported to NHS England Area Teams (ATs) is designed to provide useful information to commissioners. The reporting periods for the New Medicine Service (NMS) are: 1 April 30 June 1 July 30 September 1 October 31 December 1 January 31 March NHS England has approved the reporting template that contractors must use to report information to ATs and the approved method for submitting the form is electronic. Each participating pharmacy must ensure that the completed template is available to be requested after the end of ten working days from the last day of that quarter (i.e. the last day of June, September, December and March). Completed templates must be provided to the AT on request (which may be an ongoing request). The completed templates may also be requested by the Secretary of State. Each data must be completed using data from pharmacy records for each patient that exits the service in the relevant reporting period, regardless of when the patient enters the service. This includes: patients who decline the offer of the service at the patient engagement patients who agree to take part at patient engagement but who do not have an intervention because they withdraw consent, do not attend, are not contactable or the prescriber has stopped the medicine patients who complete a full service intervention in the reporting period. For example, if a patient is recruited to the service at patient engagement in June but completes the service in July, then they should be included in the 1 July 30 September reporting period. 1

3 a Pharmacy ODS code ODS code of the pharmacy providing the NMS. Identify the pharmacy. Alphanumeric b Pharmacy name Name of the pharmacy providing the NMS. Identify the pharmacy. Text c Pharmacy address First line of the postal address of the pharmacy Identify the pharmacy. Text (1 st line) providing the NMS. PE d (i) Patient engagement number of patients declined offer of service Number of patients who were eligible for the service but declined the offer of the service at the patient engagement. offered the service. PE d (ii) Patient engagement number of patients recruited I e (i) Intervention number of patients DNA/noncontactable/withdrew consent I e (ii) Intervention number of patients whose prescriber has stopped medicine I e (iii) Intervention number of completed interventions Number of patients who were eligible for the service and were recruited at the patient engagement. Number of patients (taken from those recruited at d (ii)), who having agreed a time and location for the intervention of the service during patient recruitment, did not take part because they withdrew their consent, or they did not attend, were non contactable (despite the pharmacist making at least one attempt to follow up with the patient) or they did not have the consultation for another reason (NMS dataset h. b-e). Number of patients (taken from those recruited at d (ii)) who were recruited to the service at patient engagement but the discussion at the intervention did not take place because the prescriber stopped one or more of their new medicine(s) (NMS dataset h. a). Number of patients (taken from those recruited at d (ii)) who complete the intervention of the service (i.e. those recruited who did not withdraw from the service due to reasons in section h of the dataset.) offered the service did not complete the service. did not complete the service. completed the service. 2

4 I e (iv) Intervention number of patients to whom information was provided Number of patients to whom information was provided on their medicine(s) by the pharmacist during the discussion at the intervention of the service. The NMS dataset codifies circumstances where information is provided (NMS dataset j. a. i-viii): interactions with other medicines why am I using the medicine/what is it for? how to use the medicine correct dose of the medicine effects of the medicine on the body/how it works why should I take the medicine? timing of the dose interpretation of side effect information. Where the pharmacist provides the patient with information and provides the patient with advice (data e (v)) then this should be recorded against both categories. The sum total for the information provided to the patient and advice provided to the patient at the intervention may therefore be higher than the total number of patients receiving the intervention. received information during the service. 3

5 I e (v) Intervention number of patients to whom advice was provided I e (vi) Intervention number of yellow card reports submitted to MHRA I e (vii) Intervention number of reminder charts/mar charts provided to patients Number of patients to whom advice was provided on their medicine(s) by the pharmacist during the discussion at the intervention of the service. The NMS dataset codifies circumstances where advice is provided (NMS dataset j. a. ix-xi): reminder strategies to support use of medicine change to timing of doses to support adherence how to manage or minimise side effects. Where the pharmacist provides the patient with advice and provides the patient with information (data e (iv)) then this should be recorded against both categories. The sum total for the information provided to the patient and advice provided to the patient at the intervention may therefore be higher than the total number of patients receiving the intervention. The number of yellow card reports submitted by the pharmacist/pharmacy contractor to the MHRA as a result of discussions with patients at the intervention of the service (NMS dataset j. a. xii). The number of reminder charts/mar charts provided to patients as a result of discussions with patients at the intervention of the service (NMS dataset j. a. xiii). received advice during the service. how many yellow card reports were submitted to the MHRA. how many reminder charts or MAR charts were provided to patients. 4

6 I e (viii) Intervention number of patients referred to GP FU f (i) Follow up number of patients DNA/noncontactable/withdrew consent FU f (ii) Follow up number of patients whose prescriber has stopped medicine FU f (iii) Follow up number of patients adherent Number of patients who had a problem identified at the intervention of the service and were referred to the GP practice for review (NMS dataset j. a. xiv). This includes patients who were referred to the GP practice for one or more medicine(s) but one or more other medicine(s) did not necessitate referral and the patient moved on to the follow up of the service for those medicine(s). Number of patients (taken from those at e (iii)) who, having agreed a time and location for the follow up of the service during the intervention, did not have the discussion with the pharmacist because they withdrew their consent to take part or they did not attend, were non contactable (despite the pharmacist making at least one attempt to follow up with the patient) or the consultation did not take place for another reason (NMS dataset k. b-e). Number of patients (taken from those at e (iii)) who having agreed a time and location for the follow up of the service at the intervention, did not take part in the discussion with the pharmacist because the prescriber stopped one or more of their new medicine(s) (NMS dataset k. a). Number of patients who at the follow up were adherent to all their medicine(s) (NMS dataset l. a). referred to the GP practice. did not complete the follow up. did not complete the follow up. adherent. 5

7 FU f (iv) Follow up number of patients non adherent FU f (v) Follow up number of patients to whom information was provided Number of patients who at the follow up were non-adherent to their medicine(s) (NMS dataset l. b). patient has not started using the medicine prescriber has stopped new medicine patient is not using the medicine in line with the directions of prescriber patient reports missing a dose in the past seven days. Number of patients to whom information was provided on their medicine(s) by the pharmacist during the discussion at the follow up of the service (NMS dataset m. a. i-viii). Information includes: interactions with other medicines why am I using the medicine/what is it for? how to use the medicine correct dose of the medicine effects of the medicine on the body/how it works why should I take the medicine? timing of the dose interpretation of side effect information. Where the pharmacist provides the patient with information and provides the patient with advice (data f (vi)) then this should be recorded against both categories. The sum total for the information provided to the patient and advice provided to the patient at the follow up may therefore be higher than the total number of patients receiving the follow up. non-adherent. received information during the service. 6

8 FU f (vi) Follow up number of patients to whom advice was provided FU f (vii) Follow up number of yellow card reports submitted to MHRA FU f (viii) Follow up number of reminder charts/mar charts provided to patients FU f (ix) Follow up number of patients referred to GP Number of patients to whom advice was provided on their medicine(s) by the pharmacist during the discussion at the follow up of the service (NMS dataset m. a. ix-xi). Advice includes: reminder strategies to support use of medicine change to timing of doses to support adherence how to manage or minimise side effects. Where the pharmacist provides the patient with advice and provides the patient with information (data f (v)) then this should be recorded against both categories. The sum total for the information provided to the patient and advice provided to the patient at the follow up may therefore be higher than the total number of patients receiving the follow up. The number of yellow card reports submitted by the pharmacist/pharmacy contractor to the MHRA as a result of discussions with patients at the follow up of the service (NMS dataset m. a. xii). The number of reminder charts/mar charts provided to patients as a result of discussions with patients at the follow up of the service (NMS dataset m. a. xiii). Number of patients who had a problem identified at the follow up of the service and were referred to the GP practice for review for one or more NMS medicine(s) (NMS dataset m. a. xiv). Patients may be using other medicine(s) for which they are not referred to the GP practice. receive advice during the service. how many yellow card reports were submitted to the MHRA. how many reminder charts or MAR charts were provided to patients. referred to the GP practice. 7

9 P g (i) Number of patients in each group asthma/ COPD P g (ii) Number of patients in each group antiplatelet/ anticoagulant P g (iii) Number of patients in each group hypertension Number of patients who were recruited to the service (data d (ii)) and were prescribed an asthma/copd NMS eligible medicine for asthma/copd. Patients prescribed more than one NMS eligible medicine NMS Medicines list) for an NMS eligible condition should be counted against each condition for which they were prescribed a medicine. The figures for each condition area may therefore be higher than the total number of patients receiving the service. Number of patients who were recruited to the service (data d (ii)) and were prescribed an antiplatelet/ anticoagulant NMS eligible medicine NMS Medicine list) for antiplatelet/ anticoagulant therapy. Patients prescribed more than one NMS eligible medicine for an NMS eligible condition should be counted against each condition for which they were prescribed a medicine. The figures for each condition area may therefore be higher than the total number of patients receiving the service. Number of patients who were recruited to the service (data d (ii)) and were prescribed a hypertension NMS eligible medicine NMS Medicine list) for hypertension. Patients prescribed more than one NMS eligible medicine for an NMS eligible condition should be counted against each condition for which they were prescribed a medicine. The figures for each condition area may therefore be higher than the total number of patients receiving the service. prescribed an NMS eligible medicine for asthma/copd. prescribed an NMS eligible medicine for anticoagulant therapy. prescribed an NMS eligible medicine for hypertension. 8

10 P g (iv) Number of patients in each group type 2 diabetes h Claims number of completed NMS claimed for HL i (i) Healthy lifestyle advice (number) engagement Number of patients who were recruited to the service (data d (ii)) and were prescribed a type 2 diabetes NMS eligible medicine NMS Medicines list) for type 2 diabetes. Patients prescribed more than one NMS eligible medicine for an NMS eligible condition should be counted against each condition for which they were prescribed a medicine. The figures for each condition area may therefore be higher than the total number of patients receiving the service. Number of full service interventions completed in the reporting period for which the pharmacy claimed payment. This should be equal to the total number of claims on the three FP34c submission documents for the three months of the reporting period. Number of patients to whom, during the reporting period, healthy lifestyle advice was given by the pharmacist at the patient engagement of the service (NMS dataset g). Healthy lifestyle advice can include: diet and nutrition smoking physical activity alcohol sexual health weight management. prescribed an NMS eligible medicine for type 2 diabetes. how many full service interventions were completed. received healthy lifestyle advice. 9

11 HL i (ii) Healthy lifestyle advice (number) intervention HL i (iii) Healthy lifestyle advice (number) follow up Number of patients to whom, during the reporting period, healthy lifestyle advice was given by the pharmacist at the intervention of the service (NMS dataset g). Healthy lifestyle advice can include: diet and nutrition smoking physical activity alcohol sexual health weight management. Number of patients to whom, during the reporting period, healthy lifestyle advice was given by the pharmacist at the follow up of the service (NMS dataset g). Healthy lifestyle advice can include: diet and nutrition smoking physical activity alcohol sexual health weight management. received healthy lifestyle advice. received healthy lifestyle advice. 10

12 Key: PE patient engagement I intervention FU follow up P number of patients in each group HL healthy lifestyle advice Further information about the reporting spreadsheet Please note that, due to the way the data is recorded (and because some patients can be recorded in multiple columns per section), most sections of the reporting spreadsheet can not be summed. 11

13 NHS Employers NHS Employers 50 Broadway London SW1H 0DB 2 Brewery Wharf Kendell Street Leeds LS10 1JR Pharmaceutical Services Negotiating Committee info@psnc.org.uk Times House 5 Bravingtons Walk London N1 9AW Published December NHS Employers This document may not be reproduced in whole or in part without permission. The NHS Confederation (Employers) Company Ltd. Registered in England. Company limited by guarantee: number Ref: EGU123901

NHS community pharmacy advanced services Briefing for GP practices

NHS community pharmacy advanced services Briefing for GP practices August 2013 This document has been developed jointly by NHS Employers, the Pharmaceutical Services Negotiating Committee (PSNC) and the